ECOR | electroCore, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	11.18 - 11.72
52 Week Range	5.02 - 14.20
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	23,708
Average Volume	81,336
Shares Outstanding	6,554,590
Market Cap	74,460,142
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2018-06-22

Valuation
Profitability
Growth
Health
P/E Ratio	-6.53
Forward P/E Ratio	N/A
EPS	-1.74
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	68
Country	USA
Website	ECOR

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

ECOR's peers: VNRX, SSKN, SGHT, DYNT, AZYO, NPCE, IRIX, NVNO, PETV, TLIS, TNON, TIVC, BJDX, HSCS, NUWE, BBLG, VVOS, RPID

*Chart delayed

Analyzing fundamentals for ECOR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is weak. For more detailed analysis please see ECOR Fundamentals page.

Watching at ECOR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ECOR Technicals page.